

Evotec SE (EVT) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/E2A47EF81EEEN.html

Date: May 2021

Pages: 64

Price: US\$ 125.00 (Single User License)

ID: E2A47EF81EEEN

Abstracts

Evotec SE (EVT) - Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.



Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Evotec SE (Evotec) is a drug discovery alliance and development partnership company. It discovers and develops small molecule drugs across various therapeutic areas such as, oncology, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory diseases. Evotec provides drug discovery services such as target identification and validation, hit identification, sample management, in vitro pharmacology services, integrated CMC and proteomics services. The company has long-term discovery alliances with several leading pharmaceutical companies and also has development partnerships for product candidates in clinical and pre-clinical development stages. The company has operating facilities in Abingdon and Alderley Park, the UK; Gottingen and Munich, Germany; Orth an der Donau, Austria; Branford, Princeton and Watertown, the US; Verona, Italy; and Toulouse and Lyon, France. Evotec is headquartered in Hamburg, Germany.

Evotec SE Key Recent Developments

May 11,2021: Evotec reports results for the first quarter 2021 and provides corporate update

Apr 27,2021: Awakn Life Sciences initiates new chemical entity development program with Evotec as research partner and addiction expert, Prof. David Nutt, as program lead



Apr 23,2021: Chairman of the Supervisory Board of Evotec to resign from office effective as of the end of the Annual General Meeting on 15 June 2021

Apr 20,2021: Evotec accelerates access to biologic therapeutics with initiation of manufacturing facility in Toulouse

Apr 13,2021: Evotec launches 'BeLAB2122', translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the



revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Evotec SE - Key Facts

Evotec SE - Key Employees

Evotec SE - Key Employee Biographies

Evotec SE - Major Products and Services

Evotec SE - History

Evotec SE - Company Statement

Evotec SE - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

SECTION 2 - COMPANY ANALYSIS

Company Overview

Evotec SE - Business Description

Business Segment: EVT Execute Segment

Overview

Performance

Business Segment: EVT Innovate Segment

Overview

Performance

Business Segment: Transition

Overview

Performance

Geographical Segment: France

Performance

Geographical Segment: Germany

Performance

Geographical Segment: Rest of the World

Performance

Geographical Segment: The UK

Performance

Geographical Segment: The US

Performance R&D Overview



Evotec SE - Corporate Strategy

Evotec SE - SWOT Analysis

SWOT Analysis - Overview

Evotec SE - Strengths

Evotec SE - Weaknesses

Evotec SE - Opportunities

Evotec SE - Threats

Evotec SE - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Evotec SE, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Evotec SE, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Evotec SE, Recent Deals Summary

SECTION 5 - COMPANY'S RECENT DEVELOPMENTS

May 11, 2021: Evotec reports results for the first quarter 2021 and provides corporate update

Apr 27, 2021: Awakn Life Sciences initiates new chemical entity development program with Evotec as research partner and addiction expert, Prof. David Nutt, as program lead Apr 23, 2021: Chairman of the Supervisory Board of Evotec to resign from office effective as of the end of the Annual General Meeting on 15 June 2021

Apr 20, 2021: Evotec accelerates access to biologic therapeutics with initiation of manufacturing facility in Toulouse

Apr 13, 2021: Evotec launches 'BeLAB2122', translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb

Mar 25, 2021: Evotec fiscal year 2020 results: Gaining speed on 'The Data-Driven R&D Autobahn to Cures'

Mar 18, 2021: Evotec SE to announce results for fiscal year 2020 on 25 March 2021



Mar 01, 2021: Evotec and Chinook Therapeutics enter into strategic collaboration to discover and develop novel precision medicines for chronic kidney diseases

Feb 01, 2021: Evotec CSO Cord Dohrmann appointed to German Council of Science and Humanities

Jan 27, 2021: Evotec Biologics expands contract with the Department of Defense for manufacturing of monoclonal antibodies

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer



List Of Tables

LIST OF TABLES

Evotec SE, Key Facts

Evotec SE, Key Employees

Evotec SE, Key Employee Biographies

Evotec SE, Major Products and Services

Evotec SE, History

Evotec SE, Subsidiaries

Evotec SE, Joint Venture

Evotec SE, Key Competitors

Evotec SE, Ratios based on current share price

Evotec SE, Annual Ratios

Evotec SE, Annual Ratios (Cont...1)

Evotec SE, Annual Ratios (Cont...2)

Evotec SE, Interim Ratios

Evotec SE, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Evotec SE, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Evotec SE, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios



List Of Figures

LIST OF FIGURES

Evotec SE, Performance Chart (2016 - 2020)

Evotec SE, Ratio Charts

Evotec SE, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Evotec SE, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



I would like to order

Product name: Evotec SE (EVT) - Financial and Strategic SWOT Analysis Review

Product link: https://marketpublishers.com/r/E2A47EF81EEEN.html

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/E2A47EF81EEEN.html